share_log

Eli Lilly and Co | 8-K: Eli Lilly Reports Second Quarter 2024 Financial Results

Eli Lilly and Co | 8-K: Eli Lilly Reports Second Quarter 2024 Financial Results

禮來 | 8-K：禮來公佈2024年第二季度財務業績
美股SEC公告 ·  08/08 07:09
Moomoo AI 已提取核心訊息
Eli Lilly and Co (LLY) reported a significant increase in its financial results for the second quarter of 2024, with revenue surging 36% to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company's earnings per share (EPS) also saw a substantial rise, with reported EPS up 68% to $3.28 and non-GAAP EPS increasing 86% to $3.92. This performance led to an upward revision of the full-year revenue guidance by $3 billion and EPS guidance by $2.05 to $2.60. The quarter also marked progress in the company's pipeline, including the U.S. FDA approval of Kisunla for Alzheimer's disease and Jaypirca in Japan for mantle cell lymphoma. Additionally, the company submitted tirzepatide for obstructive sleep apnea and obesity in the U.S. and EU, and reported positive results from a Phase 3 trial for heart failure with preserved ejection fraction and obesity. Eli Lilly's financial outlook for 2024 has improved, with revenue guidance now ranging from $45.4 to $46.6 billion and EPS guidance between $15.10 to $15.60 on a reported basis, and $16.10 to $16.60 on a non-GAAP basis.
Eli Lilly and Co (LLY) reported a significant increase in its financial results for the second quarter of 2024, with revenue surging 36% to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company's earnings per share (EPS) also saw a substantial rise, with reported EPS up 68% to $3.28 and non-GAAP EPS increasing 86% to $3.92. This performance led to an upward revision of the full-year revenue guidance by $3 billion and EPS guidance by $2.05 to $2.60. The quarter also marked progress in the company's pipeline, including the U.S. FDA approval of Kisunla for Alzheimer's disease and Jaypirca in Japan for mantle cell lymphoma. Additionally, the company submitted tirzepatide for obstructive sleep apnea and obesity in the U.S. and EU, and reported positive results from a Phase 3 trial for heart failure with preserved ejection fraction and obesity. Eli Lilly's financial outlook for 2024 has improved, with revenue guidance now ranging from $45.4 to $46.6 billion and EPS guidance between $15.10 to $15.60 on a reported basis, and $16.10 to $16.60 on a non-GAAP basis.
禮來公司（LLY）於2024年第二季度業績中報告財務業績顯著增長，營業收入增長36％至113億美元，主要由Mounjaro，Zepbound和Verzenio的強勁銷售推動。公司每股收益（EPS）也有顯著增長，報告EPS上升68％至3.28美元，非GAAP EPS增長86％至3.92美元。這一表現導致全年營收指引上調30億美元，每股收益指引上調2.05至2.60美元。此季度還標誌着公司管線進展，包括Kisunla獲得美國FDA批准用於治療阿爾茨海默病，Jaypirca在日本用於曼託細胞淋巴瘤。此外，公司還向美國和歐盟提交了tirzepatide用於治療阻塞性睡眠呼吸暫停和肥胖症，並報告了對保留射血分數和肥胖症的心力衰竭進行的第3期試驗的積極結果。禮來公司2024年的財務前景有所改善，報告基礎上的營收指引現在區間爲454億至466億美元，每股收益指引在15.10至15.60美元之間，非GAAP基礎上在16.10至16.60美元之間。
禮來公司（LLY）於2024年第二季度業績中報告財務業績顯著增長，營業收入增長36％至113億美元，主要由Mounjaro，Zepbound和Verzenio的強勁銷售推動。公司每股收益（EPS）也有顯著增長，報告EPS上升68％至3.28美元，非GAAP EPS增長86％至3.92美元。這一表現導致全年營收指引上調30億美元，每股收益指引上調2.05至2.60美元。此季度還標誌着公司管線進展，包括Kisunla獲得美國FDA批准用於治療阿爾茨海默病，Jaypirca在日本用於曼託細胞淋巴瘤。此外，公司還向美國和歐盟提交了tirzepatide用於治療阻塞性睡眠呼吸暫停和肥胖症，並報告了對保留射血分數和肥胖症的心力衰竭進行的第3期試驗的積極結果。禮來公司2024年的財務前景有所改善，報告基礎上的營收指引現在區間爲454億至466億美元，每股收益指引在15.10至15.60美元之間，非GAAP基礎上在16.10至16.60美元之間。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息